A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Exclusion criteria

• ✕. Systemic chemotherapy and anticancer therapies within 4 weeks or 5 half-lives of the drug, whichever is shorter.
• ✕. Antibody-based anticancer therapy: ≥ 4 weeks. Note: Treatment with systemic corticosteroids ≤ 25 mg/day (prednisone or equivalent) and inhaled or topical steroids are allowed. For participants with CRPC, LHRH agents are allowed.
• ✕. Participants who are HIV-positive with undetectable HIV RNA and at least 3 months on antiretroviral therapy.
• ✕. Participants with a positive serologic test for HBV (i.e., positive HBcAb and negative HBsAg) and have a negative PCR test.
• ✕. Participants who are HCV-positive who have completed at least 1 month of highly effective antiviral therapy and have a negative PCR test.